Press Release
June 25, 2025
Under the umbrella of Saudi Arabia’s National Biotechnology Strategy and as part of the high-
level MoU signings at the Saudi Pavilion during the BIO International Convention 2025 in
Boston, Massachusetts, Novo Genomics and Avigena signed a landmark Memorandum of
Understanding (MoU) on June 16, 2025.
This agreement reflects the Kingdom’s bold commitment to global collaboration and innovation-driven healthcare transformation. The MoU marks a strategic partnership between Avigena, a U.S.-based genomic medicine
company specializing in polygenic risk scores (PRS) and preventive health solutions, and Novo
Genomics, a Saudi Arabian biotechnology leader in genomics, multi-omics, and precision
medicine. Together, the two companies will collaborate to deliver cutting-edge genomic testing
and personalized health services tailored for Arab populations, focusing on cardiovascular
disease, cancer, and diabetes risk prediction.
This partnership will serve both the public (B2G) and private (B2B/B2C) healthcare sectors,
positioning Novo Genomics and Avigena as regional leaders in predictive and preventive
genomics. The collaboration also integrates high-resolution genomic science with culturally
sensitive virtual care technologies—including genetic counseling, health coaching, and risk
reporting—to transform the future of healthcare delivery across Saudi Arabia, the GCC, and the
broader MENA region.
By combining their strengths, Novo Genomics and Avigena aim to localize genomic innovation,
support national health initiatives, and scale access to personalized, preventive care across the
region.